### **Overview** Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India. Founded in 1990 and publicly listed on the BSE and NSE, Strides specializes in the development, manufacturing, and commercialization of complex generics, value-added formulations, and differentiated pharmaceutical products. The company serves over **100 countries** across regulated, emerging, and donor-funded institutional markets, with a strategic focus on niche, technically complex drugs that face low competition and high barriers to entry. --- ### **Core Business Segments and Markets** Strides operates across three primary market segments: 1. **Regulated Markets (U.S., UK, EU, Canada, Australia)** - Accounts for **53% of total revenue** (as of FY 2024–25), with the **U.S. as its largest and most strategic market**. - Generated $291 million in revenue from the U.S. in FY 2024–25, growing **21.8% YoY** in rupee terms. - Other Regulated Markets (ORM), including UK, Europe, and Australia, reported **13.5% YoY revenue growth**, reaching ₹13,585 million in FY 2024–25. - Revenue from Australia is driven by a **10-year strategic supply agreement** with Arrotex, the country’s leading generics player. 2. **Growth & Emerging Markets (Africa, LATAM, APAC, MENA, CIS)** - The Africa business remains central to Strides’ long-term strategy, supported by its **'In Africa for Africa' model**. - The Nairobi facility in Kenya is one of only **two WHO-prequalified manufacturing sites in Sub-Saharan Africa**, enabling local production and supply to African governments and donor programs. - The segment reported **24.2% YoY growth**, reaching ₹4,927 million ($59 million) in FY 2024–25. 3. **Institutional/Access Markets (Donor-Funded Programs)** - Supplies affordable ARVs, anti-malarials, and Hepatitis treatments to global health organizations including the **Global Fund, PEPFAR, USAID, WHO, and UNICEF**. - Manufactures TLD (Tenofovir, Lamivudine, Dolutegravir), a first-line HIV regimen, and has delivered **8.45 million treatments globally** by end-FY24. - Plans to supply over **100 million TLD tablets each from India and Kenya sites** in FY26. --- ### **Growth Strategy and Commercial Focus (2025–2028)** Strides’ growth is anchored in a **three-pronged strategy** across markets and product innovation: #### **1. U.S. Market Expansion – $400 Million Target** - **Portfolio leverage**: 230+ ANDAs filed, with over **215 approved**. Currently commercializes **73 products**, with **36 ranked in the top three** by market share. - Strategy emphasizes **relaunching dormant ANDAs**: Targeting **60 products** over the next three years to achieve **$400 million in U.S. revenue by FY27–28**. - Focus on **complex generics**, 505(b)(2) filings, controlled substances, modified-release drugs, nasal sprays, and combination therapies to avoid commoditization. #### **2. Product Diversification & Innovation** - Active development in **505(b)(2) pathway drugs**, enabling faster approval of new dosage forms or combinations of approved APIs. - Launched a combination product in FY 2024–25 with meaningful revenue impact. - Filed its **first nasal spray product with the USFDA** in Q1 FY 2025–26, signaling entry into high-growth, high-barrier drug delivery systems. - Partnering with **Kenox Pharmaceuticals** to co-develop nasal spray pipeline for the U.S., combining Kenox’s formulation expertise with Strides’ manufacturing and commercial strengths. #### **3. Global Market Mirroring** - Aims to replicate U.S.-level performance in **Other Regulated Markets (ORM)**, targeting another **$400 million revenue stream** in Europe and Australia. - Expanding B2B partnerships in Germany, France, Netherlands, Poland, and Hungary. Deepening UK presence via subsidiaries and NHS tenders. - In Latin America and CIS, re-entering markets using existing product registrations and local partnerships. --- ### **R&D and Product Development** - R&D strategy emphasizes: - **Complex formulations** (modified-release tablets, nasal sprays, oral suspensions, topicals, controlled substances). - **Scientific excellence**, **quality compliance**, and **cost optimization**. - Patient-centric innovations to improve adherence and therapy outcomes. - Key achievements in FY 2024–25: - **7 approvals** each from USFDA, EU, and MHRA. - **1 ANDA in EU**, **6 in UK (MHRA)** filed. - Developed **malarial rectal suppositories** for pediatric emergency use. - Advancing an **innovative antihypertensive combination therapy** to reduce pill burden. - Filed **NDA for an HIV therapy** targeting unmet needs in resource-limited regions. --- ### **Manufacturing and Operational Excellence** Strides operates a **global manufacturing network** with **seven facilities across four continents**: | Location | Key Features | |--------|-------------| | **India (Bengaluru ×2, Chennai, Puducherry)** | Flagship KRSG plant; US FDA, MHRA, TGA, WHO compliant; high-speed soft gel and liquid production | | **New York, USA (Chestnut Ridge)** | DEA-registered; produces controlled substances, nasal sprays, and hormones; TAA-compliant for U.S. federal contracts | | **Milan, Italy** | Supplies EU markets | | **Nairobi, Kenya (UCL)** | WHO-prequalified for 13 consecutive years; supports “In Africa for Africa” strategy and donor-funded supply | - **Digital Transformation**: - Implementation of **Manufacturing Execution System (MES)** enabling electronic batch records and “Review by Exception” for faster batch releases. - Adoption of **AI, machine learning, and generative AI** to reduce OOS instances, optimize analyst allocation, automate CSV, and accelerate root cause analysis. - Migration to a **hybrid and multicloud IT infrastructure** to support digital innovation. --- ### **Subsidiaries and Strategic Platforms** #### **1. OneSource Specialty Pharma Limited** - Formerly Stelis Biopharma, spun out as a **pure-play CDMO**. - Focus areas: **biologics, sterile injectables, soft gelatin capsules, and drug-device combinations**. - Five USFDA/EU-approved facilities, 1,200+ employees, **40+ global clients**, including 15 in GLP-1 development. - Projected FY25 revenue: **$175–190 million**, EBITDA: **$60–65 million**. - Positioned as one of **India’s top 5 specialty CDMOs**, offering **integrated DS-DP (drug substance–drug product)** capabilities. #### **2. Arcolab** - Strides’ **technology and life sciences consulting arm**. - Over **500 domain experts**, serving **30+ clients globally**. - Offers end-to-end services in regulatory compliance, automation, clinical operations, and AI-driven solutions. - Deployed **RPA across 125 processes**, achieving **30% cost reduction**. - Investing in **AI-driven product development** and expanding into pharmacovigilance and clinical services. --- ### **Key Products & Pipeline Highlights** - **HIV & Infectious Diseases**: - Leading supplier of **TLD (Dolutegravir-based)** under MPP-ViiV license. - Supplies ARVs and anti-malarials (including **Artesunate rectal capsules**) to 105+ developing countries. - **Softgel Capsules**: - Among **world’s top 4 manufacturers**, with an annual capacity of **2.4 billion units**. - Portfolio addresses $2.5 billion market; five NCE-1 products expected to go off-patent in coming years. - **Innovative Formulations**: - Developing **non-invasive malarial suppositories** and **novel antihypertensive combinations**. - Focused on **fixed-dose combinations**, bioequivalent multi-drug therapies, and **first-to-file opportunities**.